Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States
Antibiotics · 22.07.2026 · 15 (7) · 710
DOI: 10.3390/antibiotics15070710 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 22.07.2026. Verfasst von Inès Fenniri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Harvard-wide Program on Antibiotic Resistance, Innovate2Impact Award, Fondation de France.
Abstract (Originalsprache)
Severe bacterial keratitis and endophthalmitis are leading causes of corneal scarring, enucleation, and permanent vision loss, and are increasingly complicated by multidrug-resistant Gram-positive ocular pathogens. In the United States, according to the ARMOR surveillance program (2009–2020), methicillin resistance reached 45.9% of intraocular Staphylococcus aureus and 47.9% of coagulase-negative staphylococci (CoNS), with multidrug resistance exceeding 70% among methicillin-resistant intraocular isolates. While new antibiotics have been approved for systemic infections, vancomycin remains the standard of care for severe Gram-positive ocular infections. However, its ophthalmic use is constrained by limited ocular surface tolerability, physical incompatibility with intravitreal ceftazidime, and an association with hemorrhagic occlusive retinal vasculitis. To address this gap and further stimulate the development of next-generation targeted therapies in ophthalmology, this review focuses on current recommendations and new vancomycin alternative treatments for Gram-positive ocular infections in the antibiotic resistance era. This review details the current antimicrobial recommendations for the most frequent ocular infections, followed by the epidemiology and molecular mechanisms of resistance in S. aureus, CoNS, and S. pneumoniae. Finally, this review discusses new drugs that represent promising alternatives to vancomycin in ophthalmology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA.
- Infectious Disease Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.
- Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
- Department of Ophthalmology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 5 Place d'Arsonval, 69003 Lyon, France.
ORCID-Profile: Inès Fenniri
Förderung
- Harvard-wide Program on Antibiotic Resistance
- Innovate2Impact Award
- Fondation de France
Zitieren
APA
Fenniri, I., & André, C. (2026). Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States. Antibiotics, 15(7), 710. https://doi.org/10.3390/antibiotics15070710
Vancouver
Fenniri I, André C. Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States. Antibiotics. 2026;15(7):710. doi:10.3390/antibiotics15070710
BibTeX
@article{Fenniri2026,
author = {Fenniri, Inès and André, Camille},
title = {Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {7},
pages = {710},
doi = {10.3390/antibiotics15070710}
}
EUVIMED